Event rates of primary and secondary outcomes in a matched cohort of patients with diabetic retinopathy prescribed ARBs and ACE inhibitors
| Outcome | ARB cohort | ACE inhibitor cohort (reference) | Hazard ratio (95% CI) | ||||
|---|---|---|---|---|---|---|---|
| No. of events | No. of person-years | Incidence rate* | No. of events | No. of person-years | Incidence rate* | ||
| All-cause death | 1 421 | 54 620 | 26.0 | 1 500 | 54 129 | 27.7 | 0.94 (0.87–1.01) |
| Major adverse cardiac events | 944 | 52 004 | 18.2 | 978 | 51 409 | 19.0 | 0.95 (0.87–1.04) |
| Myocardial infarction | 317 | 53 867 | 5.9 | 306 | 53 501 | 5.7 | 1.03 (0.88–1.20) |
| Ischemic stroke | 685 | 52 664 | 13.0 | 720 | 51 966 | 13.9 | 0.94 (0.85–1.04) |
| Cardiovascular death | 417 | 54 581 | 7.6 | 408 | 54 103 | 7.5 | 1.01 (0.88–1.16) |
| Hospital admission with acute kidney injury | 671 | 53 311 | 12.6 | 656 | 52 829 | 12.4 | 1.01 (0.91–1.13) |
| Hospital admission with hyperkalemia | 320 | 53 892 | 5.9 | 314 | 53 325 | 5.9 | 1.01 (0.86–1.18) |
Note: ACE = angiotensin-converting enzyme, ARB = angiotensin II receptor blocker, CI = confidence interval.
↵* Per 1000 person-years.